AngioDynamics (ANGO) ended fiscal 2026 second quarter with $41.6M in cash and cash equivalents, ahead of the company’s expectations. It continues to expect to be cash flow positive for the full year FY 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics reports Q2 adjusted EPS 0c, consensus (10c)
- AngioDynamics backs FY26 adjusted EPS view (33c)-(23c), consensus (33c)
- AngioDynamics says Jim Clemmer to retire during FY27 as CEO
- Options Volatility and Implied Earnings Moves This Week, January 06 – January 08, 2026
- ANGO Earnings Report this Week: Is It a Buy, Ahead of Earnings?